009290 — Kwangdong Pharmaceutical Co Income Statement
0.000.00%
- KR₩261bn
- KR₩356bn
- KR₩2tn
- 56
- 90
- 54
- 79
Annual income statement for Kwangdong Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,238,255 | 1,243,770 | 1,338,182 | 1,431,545 | 1,514,454 |
Cost of Revenue | |||||
Gross Profit | 258,668 | 257,709 | 274,253 | 282,048 | 299,827 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1,201,898 | 1,199,914 | 1,293,246 | 1,393,198 | 1,474,925 |
Operating Profit | 36,357 | 43,856 | 44,936 | 38,347 | 39,529 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 36,770 | 62,951 | 34,329 | 36,291 | 49,019 |
Provision for Income Taxes | |||||
Net Income After Taxes | 22,656 | 45,602 | 25,541 | 26,701 | 39,372 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 23,058 | 45,370 | 24,019 | 24,174 | 36,966 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 23,058 | 45,370 | 24,032 | 24,174 | 36,966 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 664 | 1,148 | 583 | 584 | 1,003 |
Dividends per Share |